U87 CART in Treatment of Advanced Solid Tumor

Inclusion Criteria

• •1. Voluntary informed consent is given;
• •2. Age 18 to 75;
• •3. Patients with pathologically confirmed advanced solid tumor who have failed first-line therapy; or patients who are intolerant to first-line standard therapy and voluntarily give up standard therapy;
• •4. Immunohistochemical (IHC) staining of tumor tissue samples from patients was positive for U87 specific antigen (≥ 2 +, and the expression rate was ≥ 20%);
• •5. Expected survival ≥12 weeks;
• •6. Measurable tumor lesions according to RECIST 1.1;
• •7. ECOG performance score 0-1;
• •8. Sufficient venous access for mononuclear cell collection;
• •9. HBc Ab positive, HBsAg negative can be included in the group when the PCR detection of HBV DNA is negative;
• •10. Patients should maintain adequate organ function;
• •11. Dyspnea (CTCAE v5.0) ≤ Grade 1; Blood oxygen saturation\>91% without oxygen inhalation;
• •12. Pregnancy test was negative in women of childbearing age; Both male and female subjects should agree to use effective contraceptives during the treatment period and within the following year;